Previous research has linked frailty to poor outcomes in older adults undergoing TAVR. Therefore, Dr Jonathan Afilalo (McGill University, Canada) and his team conducted the PERFORM-TAVR trial (NCT03522454) at 11 hospitals across Canada to explore whether a combination of nutritional supplementation and exercise could improve this situation.
The participants were ≥70 years of age and had objective evidence of physical frailty in standardised scores. The control group received lifestyle education only, while those in the intervention group received lifestyle education in addition to a protein-rich oral nutritional supplement that they consumed twice daily starting 4 weeks before TAVR and continuing for 12 weeks after TAVR. In addition, they took part in a home-based exercise intervention with a supervised component entailing home visits of an hour by a therapist twice a week for 12 weeks after TAVR complimented with an unsupervised walking programme.
The primary study endpoint was the short physical performance battery (SPPB) scale (range 0–12) at 12 weeks, which consists of a 3-part balance test, a gait speed test, and a chair stand test. “We're really looking at strength, mobility, and balance,” Dr Afilalo explained. The analysis included 180 participants with a mean age of 83 years.
The mean SPPB score at baseline was 7.1 for both groups. At 12 weeks, it improved to 8.1 in the intervention group versus 7.1 in the control group, a multivariable-adjusted difference of 0.9 points (95% CI 0.3–1.6; P=0.006). “A 1-point improvement is approximately the same effect size observed with a full-blown cardiac rehabilitation programme. Improving frailty is going to improve the outcomes of patients undergoing all sorts of interventional procedures,” Prof. Afilalo concluded.
- Afilalo J, et al. Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial. Featured Clinical Research 3, Session 413, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
Medical writing support was provided by Dr Susanne Kammerer.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« AEGIS-II: Negative primary endpoint but infusions might benefit subgroups of patients Next Article
New PCSK9 inhibitor achieves LDL-C goals in high-risk and very high-risk patients »
« AEGIS-II: Negative primary endpoint but infusions might benefit subgroups of patients Next Article
New PCSK9 inhibitor achieves LDL-C goals in high-risk and very high-risk patients »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
Online First
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
To stent or not to stent? Favourable results for preventive PCI in vulnerable atherosclerotic plaques
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
SGLT2 inhibition in heart failure more advantageous for women than men
Microaxial flow pump safes lives but comes with a price tag
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
Safety of TAVI non-inferior to SAVR in patients with lower surgical risk
New PCSK9 inhibitor achieves LDL-C goals in high-risk and very high-risk patients
Protein drinks and exercise intervention improve physical performance in frail patients undergoing TAVR
AEGIS-II: Negative primary endpoint but infusions might benefit subgroups of patients
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
RELIEVE-HF: Inter-atrial shunt might be advantageous in HFrEF
BE ACTIVE shows that small incentives increase daily steps in high-risk patients
“Inclisiran first” strategy highly effective regarding LDL control in ASCVD
Olezarsen highly effective in lowering triglycerides
Related Articles
April 17, 2024
Therapeutic strategies for bullous pemphigoid
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy